Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Aventador:
I wouldn't spend too much time on ALB1. At least he and others like him are helping to keep the SP at its present record-low level. The shares IMO are an extraordinary bargain.
Better to go back to the RNS of 18 November - "the Evolution of Immupharma" and take a look at the new sense of drive and ambition that underlines it. I think it is especially meaningful that the collaboration agreement between IMM and CNRS and Prof. Muller has been strengthened, that she is taking a close interest in the development of the CIDP 2/3 trial preparations and that they are being joined in this with the leading CIDP specialist in France in this field, Prof. de Seze. And there is much else in the RNS that makes exciting reading for LTH of IMM.
All this is going to require more working capital unless CRNS is paying for some of the research. I can't believe that IMM has not worked out where this finance is coming from before agreeing these initiatives.
My personal view is that although Prof Muller has won many academic awards for her work on peptides in general and on P140/Lupuzor in particular, she must be feeling frustrated ( to put it politely) at the lack of progress on Lupuzor, CIDP and other medical applications of P140. Hence the decision for her and CRNS to become more closely involved in IMM's R and D.
After all, it would be the crowning achievement of her professional career and her lasting legacy if success in the lab is converted into real life improvement for the many thousands who suffer from Lupus, CIDP and other diseases of the autoimmune system.
ALB1.
A change of tune from you. Much appreciated.
I notice from a post you sent a few days ago that you were accusing the BOD of being only interested in keeping up their lifestyles. Has it never occurred to you that maybe, just maybe, they are more committed to the success of IMM than you or I can possibly be. Yes, we have money at stake, but the BOD and all who work for IMM have their careers and reputations at stake as well.
Might it not be possible that they are working their guts out not only for the success of our investment but also for the millions of lupus sufferers and others (like CIDP patients) whose lives will be hugely improved if their research is successful. Moreover, if they are successful it will be a big boost to their professional reputations and careers.
So stop knocking them! Try a little patience!
Dibs & co.... i concur that IF and very big IF IMM /Avion and any other commercial partners get going on the IP then yes this could well go to the moon. Therefore - The SP now is either an absolute unbelievable once in a lifetime bargain , or a product of failure. Simples,,, either way i do believe the SP is being rather manipulated here and should be at least double IMO.
Cauldstream - yes the doomsters are very active here and forecasting the worst possible outcome on…. well everything really! I take the view that the potential downside from here is limited - not impossible of course - but limited. We may in fact be near or at the bottom now. When sentiment on a BB is at rock bottom that can be a useful pointer in that regard.
As regards the CLN’s no doubt they will cobble together some kind of a solution. If my research is correct it appears they have substantially more than £700k in the bank currently. So I assume that they could choose to pay it off subject to the liquidity being in place. But as I say no doubt it will be sorted without any hysteria. At least then poor suffering ALB will be able to sleep at night.
I am hoping for a positive announcement or two prior to Christmas.
It's hard to get away from the conviction that ALB1 and his followers are no other than imitations of Private Fraser, the dour undertaker in Dad's Army who near the beginning of most episodes would intone "WE'RE DOOMED, DOOMED!". And at the end, when all turned out well thanks to the fortitude of his fellow members of the local Home Guard, would tell anyone who would listen "I always said that it would turn out all right!"
Myy prediction is that around the middle of 2022, when IMM has completed the PK Study and the Phase 3 of Lupuzor is underway, when a commercial partner has come on board to give impetus to the CIDP programme and another partner has been found to launch the BioAMP product, the same doomsters will be telling us that they predicted this success all the time.
So as Nolupus advised, let them get on with it instead of constantly sniping at them.